Jefferies analyst David Steinberg says his survey of 25 high-volume physicians regarding the treatment landscape for thyroid eye disease indicates the potential for rapid uptake of Horizon Pharma's teprotumumab. The responses suggest not only high unmet need for this rare condition but also a "unanimous view" that teprotumumab is disease modifying, Steinberg tells investors in a research note. He believes the antibody could be priced at a premium to his $100,000 per treatment forecast, assuming approval in the first half of 2020. Steinberg keeps a Buy rating on Horizon Pharma with a $34 price target.